Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma

This study is tracking how well a liver cancer treatment procedure called TACE (transarterial chemoembolization — where anti-cancer drugs are delivered directly into the blood vessels feeding the tumor) works in patients with primary liver cancer that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have primary liver cancer (hepatocellular carcinoma) that cannot be removed with surgery, and you have not received any prior treatment - OR your liver cancer came back after a curative treatment and you have not received any post-treatment therapy - You have adequate liver function (Child-Pugh A) and your tumor occupies less than 50% of the liver - You have a single tumor 10 cm or smaller, or up to 10 tumors, with good overall organ function **You may NOT be eligible if...** - Your tumor makes up more than 50% of your liver volume - You have had complications like brain confusion from liver failure, severe fluid in the abdomen, or bleeding from the esophagus - You have cancer that has spread outside the liver - You have HIV or syphilis - You have had another cancer in the past 5 years - You are pregnant or breastfeeding - You cannot take oral medications Talk to your doctor to see if this trial is right for you.